Clinical Genomics
In session I of Myeloma2018, Suzanne Trudel, MD, FRCPC, Jens Lohr, MD, PhD, Angela Dispenzieri, MD, Ola Landgren, MD, PhD, and Daniel AuClair, PhD, provide updates on important, non-invasive genome profiling techniques to determine key markers in patients with multiple myeloma. Clinical trial results are discussed, as are the effectiveness of techniques such as cell-free disease assessment, MRD testing, and V(D)J based MRD tracking.
Princess Margaret Cancer Centre, University of Toronto, Toronto, Canada
Suzanne Trudel, MD, from the Princess Margaret Cancer Centre, University of Toronto, Toronto, Canada, speaks about cell-free DNA.
Dana-Farber Cancer Institute, Boston, MA
Jens Lohr, MD, PhD, from the Dana-Farber Cancer Institute, Boston, MA, talks about cell-free disease assessment.
Mayo Clinic, Rochester, MN
Angela Dispenzieri, MD, from the Mayo Clinic, Rochester, MN, discusses the MRD detection method of mass spectrometry, and monoclonal proteins.
Memorial Sloan Kettering Cancer Center, New York, NY
Ola Landgren, MD, PhD, from the Memorial Sloan Kettering Cancer Center, New York, NY, speaks about the MSKCC experience on V(D)J based MRD tracking in multiple myeloma.
Multiple Myeloma Research Foundation, Norwalk, CT
Daniel AuClair, PhD, from the Multiple Myeloma Research Foundation, Norwalk, CT, discusses precision medicine tests in multiple myeloma.